In recent years, GLP-1 receptor agonists have emerged as a hot topic in the medical field. These medications, which mimic the effects of gut hormones to regulate appetite and insulin, have shown remarkable weight loss and blood sugar-lowering effects in clinical trials. Among them, semaglutide, tirzepatide (sometimes referred to as "telpotide" in some studies, though this may be a typo), and liraglutide are three widely discussed drugs. So, which of these medications is better for weight loss? Let’s compare them from multiple dimensions.
Semaglutide (CAS 910463-68-2) and liraglutide (CAS 204656-20-2) are both GLP-1 receptor agonists. Their primary function is to activate the GLP-1 receptor, thereby slowing gastric emptying, increasing satiety, and reducing appetite. However, semaglutide is a long-acting version that requires weekly injections, while liraglutide, as a short-acting agonist, demands daily injections, making it less convenient.
Tirzepatide (CAS 2023788-19-2), on the other hand, is a dual GIP and GLP-1 receptor agonist. In addition to activating the GLP-1 receptor, it also targets the GIP receptor. This dual mechanism allows tirzepatide to enhance insulin sensitivity, suppress appetite, regulate fat metabolism, and even activate metabolic memory effects, enabling long-term weight management through multiple pathways.
Clinical trial data reveals a clear hierarchy in weight loss efficacy among the three drugs. Tirzepatide demonstrates the most significant weight loss effect, with patients losing approximately 20–22% of their body weight in obesity trials. Semaglutide follows closely, achieving an average weight loss of about 15%. Liraglutide lags behind, with an average weight loss of 8–10% when administered daily.
Head-to-head trials further highlight tirzepatide’s superiority. In the SURMOUNT-5 study, tirzepatide resulted in an average weight loss of 22.8 kg over 72 weeks, 47% higher than semaglutide’s 15 kg. Patients on tirzepatide also experienced a greater reduction in waist circumference (18.4 cm vs. 13.0 cm with semaglutide) and showed better performance in metabolic indicators such as blood pressure and blood lipids.
Semaglutide and tirzepatide both offer the convenience of weekly injections, which significantly improve patient compliance compared to liraglutide’s daily injection requirement. For individuals accustomed to a fast-paced lifestyle, the weekly dosing regimen of semaglutide and tirzepatide is undoubtedly a major advantage.
All three medications share common side effects such as nausea, vomiting, diarrhea, and constipation. However, their tolerability differs. Semaglutide and tirzepatide are generally better tolerated due to less frequent dosing and gradual titration. Liraglutide, due to its daily injection regimen, has a slightly higher incidence of side effects. Notably, tirzepatide carries a risk of pancreatitis, while semaglutide may cause hypoglycemia in some patients.
The U.S. Food and Drug Administration (FDA) has approved liraglutide (Saxenda®) and semaglutide (Wegovy®) for chronic weight management. Tirzepatide (Zepbound™/Mounjaro™) received FDA approval in 2023 specifically for obesity and overweight individuals with comorbidities. Tirzepatide is particularly suitable for severe obesity (BMI ≥ 30) or cases requiring rapid weight loss, as well as for patients with comorbidities such as hypertension and hyperlipidemia. Semaglutide is recommended for patients with cardiovascular disease, especially those requiring long-term medication with high adherence (weekly injections). Liraglutide, due to its daily injection requirement and lower weight loss efficacy, is primarily suitable for mild to moderate obesity.
As a newer drug, tirzepatide may be more expensive and harder to access. Semaglutide, though widely used, is often in high demand. Liraglutide is more accessible but less convenient due to its daily injection regimen.
If your primary goal is weight loss and you prefer a weekly dosing regimen, tirzepatide is the optimal choice, offering the most significant weight loss effect. However, if you have cardiovascular disease or prioritize long-term medication adherence, semaglutide is a suitable alternative. For patients with mild to moderate obesity seeking a cost-effective solution, liraglutide may be a viable option.
It is important to note that all medications must be used under medical supervision, and their long-term safety requires further research. Before initiating treatment, consult your healthcare provider to determine the most appropriate medication based on your individual circumstances.
Copyright © 2008-2026 LookChem.com All rights reserved.
